|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CLASP1 |
Gene summary for CLASP1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CLASP1 | Gene ID | 23332 |
| Gene name | cytoplasmic linker associated protein 1 | |
| Gene Alias | MAST1 | |
| Cytomap | 2q14.2-q14.3 | |
| Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | Q7Z460 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23332 | CLASP1 | CCI_1 | Human | Cervix | CC | 3.12e-22 | 1.32e+00 | 0.528 |
| 23332 | CLASP1 | CCI_2 | Human | Cervix | CC | 9.62e-13 | 1.06e+00 | 0.5249 |
| 23332 | CLASP1 | CCI_3 | Human | Cervix | CC | 7.16e-33 | 1.55e+00 | 0.516 |
| 23332 | CLASP1 | AEH-subject1 | Human | Endometrium | AEH | 8.72e-16 | 4.48e-01 | -0.3059 |
| 23332 | CLASP1 | AEH-subject2 | Human | Endometrium | AEH | 2.66e-05 | 3.26e-01 | -0.2525 |
| 23332 | CLASP1 | AEH-subject3 | Human | Endometrium | AEH | 2.85e-05 | 2.89e-01 | -0.2576 |
| 23332 | CLASP1 | AEH-subject4 | Human | Endometrium | AEH | 7.79e-12 | 5.26e-01 | -0.2657 |
| 23332 | CLASP1 | AEH-subject5 | Human | Endometrium | AEH | 2.78e-09 | 4.21e-01 | -0.2953 |
| 23332 | CLASP1 | EEC-subject1 | Human | Endometrium | EEC | 2.06e-08 | 4.22e-01 | -0.2682 |
| 23332 | CLASP1 | EEC-subject2 | Human | Endometrium | EEC | 3.84e-09 | 3.98e-01 | -0.2607 |
| 23332 | CLASP1 | EEC-subject4 | Human | Endometrium | EEC | 5.47e-04 | 3.20e-01 | -0.2571 |
| 23332 | CLASP1 | EEC-subject5 | Human | Endometrium | EEC | 9.71e-11 | 4.36e-01 | -0.249 |
| 23332 | CLASP1 | GSM5276934 | Human | Endometrium | EEC | 1.88e-05 | -1.19e-01 | -0.0913 |
| 23332 | CLASP1 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 2.56e-03 | 6.02e-04 | -0.1869 |
| 23332 | CLASP1 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 6.19e-04 | -8.13e-02 | -0.1875 |
| 23332 | CLASP1 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 1.28e-06 | -1.70e-02 | -0.1883 |
| 23332 | CLASP1 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 5.04e-05 | -7.49e-03 | -0.1934 |
| 23332 | CLASP1 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 2.33e-12 | -4.99e-03 | -0.1917 |
| 23332 | CLASP1 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 4.83e-11 | -3.04e-02 | -0.1916 |
| 23332 | CLASP1 | LZE4T | Human | Esophagus | ESCC | 6.58e-19 | 5.32e-01 | 0.0811 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003227118 | Prostate | BPH | regulation of protein polymerization | 80/3107 | 233/18723 | 2.67e-11 | 1.78e-09 | 80 |
| GO:003158910 | Prostate | BPH | cell-substrate adhesion | 110/3107 | 363/18723 | 4.64e-11 | 2.96e-09 | 110 |
| GO:004206018 | Prostate | BPH | wound healing | 123/3107 | 422/18723 | 5.74e-11 | 3.59e-09 | 123 |
| GO:000716316 | Prostate | BPH | establishment or maintenance of cell polarity | 75/3107 | 218/18723 | 9.93e-11 | 5.97e-09 | 75 |
| GO:015011615 | Prostate | BPH | regulation of cell-substrate junction organization | 35/3107 | 71/18723 | 1.81e-10 | 1.02e-08 | 35 |
| GO:001081017 | Prostate | BPH | regulation of cell-substrate adhesion | 74/3107 | 221/18723 | 5.40e-10 | 2.70e-08 | 74 |
| GO:00480419 | Prostate | BPH | focal adhesion assembly | 39/3107 | 87/18723 | 6.07e-10 | 2.91e-08 | 39 |
| GO:005189310 | Prostate | BPH | regulation of focal adhesion assembly | 32/3107 | 66/18723 | 1.85e-09 | 7.63e-08 | 32 |
| GO:009010910 | Prostate | BPH | regulation of cell-substrate junction assembly | 32/3107 | 66/18723 | 1.85e-09 | 7.63e-08 | 32 |
| GO:009013216 | Prostate | BPH | epithelium migration | 104/3107 | 360/18723 | 2.96e-09 | 1.15e-07 | 104 |
| GO:009013016 | Prostate | BPH | tissue migration | 105/3107 | 365/18723 | 3.21e-09 | 1.24e-07 | 105 |
| GO:001063116 | Prostate | BPH | epithelial cell migration | 103/3107 | 357/18723 | 3.80e-09 | 1.44e-07 | 103 |
| GO:000166717 | Prostate | BPH | ameboidal-type cell migration | 128/3107 | 475/18723 | 5.69e-09 | 2.05e-07 | 128 |
| GO:002241117 | Prostate | BPH | cellular component disassembly | 121/3107 | 443/18723 | 6.34e-09 | 2.25e-07 | 121 |
| GO:000195210 | Prostate | BPH | regulation of cell-matrix adhesion | 48/3107 | 128/18723 | 9.98e-09 | 3.34e-07 | 48 |
| GO:001063216 | Prostate | BPH | regulation of epithelial cell migration | 87/3107 | 292/18723 | 1.18e-08 | 3.87e-07 | 87 |
| GO:003003817 | Prostate | BPH | contractile actin filament bundle assembly | 42/3107 | 106/18723 | 1.27e-08 | 4.07e-07 | 42 |
| GO:004314917 | Prostate | BPH | stress fiber assembly | 42/3107 | 106/18723 | 1.27e-08 | 4.07e-07 | 42 |
| GO:003432910 | Prostate | BPH | cell junction assembly | 114/3107 | 420/18723 | 2.52e-08 | 7.49e-07 | 114 |
| GO:003223117 | Prostate | BPH | regulation of actin filament bundle assembly | 41/3107 | 105/18723 | 3.08e-08 | 8.91e-07 | 41 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CLASP1 | SNV | Missense_Mutation | c.2725N>T | p.His909Tyr | p.H909Y | Q7Z460 | protein_coding | deleterious(0) | possibly_damaging(0.789) | TCGA-A2-A0EV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CLASP1 | SNV | Missense_Mutation | rs748266679 | c.3997C>T | p.Arg1333Trp | p.R1333W | Q7Z460 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A8-A08J-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| CLASP1 | SNV | Missense_Mutation | c.704N>G | p.Ser235Cys | p.S235C | Q7Z460 | protein_coding | deleterious(0) | possibly_damaging(0.471) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| CLASP1 | SNV | Missense_Mutation | novel | c.1078N>T | p.Asp360Tyr | p.D360Y | Q7Z460 | protein_coding | deleterious(0) | possibly_damaging(0.789) | TCGA-AC-A3QQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CLASP1 | SNV | Missense_Mutation | novel | c.1078G>A | p.Asp360Asn | p.D360N | Q7Z460 | protein_coding | deleterious(0) | benign(0.36) | TCGA-AR-A0U2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | PD |
| CLASP1 | SNV | Missense_Mutation | rs751028676 | c.3559N>A | p.Glu1187Lys | p.E1187K | Q7Z460 | protein_coding | deleterious(0.03) | probably_damaging(0.991) | TCGA-B6-A1KN-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| CLASP1 | SNV | Missense_Mutation | c.2719N>A | p.Asp907Asn | p.D907N | Q7Z460 | protein_coding | deleterious(0) | possibly_damaging(0.887) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| CLASP1 | SNV | Missense_Mutation | c.71G>A | p.Gly24Asp | p.G24D | Q7Z460 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CLASP1 | SNV | Missense_Mutation | c.1382N>C | p.Arg461Thr | p.R461T | Q7Z460 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR | |
| CLASP1 | SNV | Missense_Mutation | novel | c.2790T>G | p.Asp930Glu | p.D930E | Q7Z460 | protein_coding | tolerated(0.6) | benign(0.031) | TCGA-LL-A441-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |